This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome (CTRAD)

This study has been completed.
Information provided by (Responsible Party):
Shaista Malik, University of California, Irvine Identifier:
First received: February 24, 2012
Last updated: December 7, 2016
Last verified: December 2016
This study looked at the role of cardiac CT in improving risk factor control in those with diabetes.

Condition Intervention
Diabetes Metabolic Syndrome Procedure: Cardiac CT Drug: Usual medical care

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Role of Cardiac CT in Risk Factor Control in Asymptomatic Patients With Diabetes

Resource links provided by NLM:

Further study details as provided by Shaista Malik, University of California, Irvine:

Primary Outcome Measures:
  • Systolic BP pressure [ Time Frame: Five year follow up ]
    After randomization to either obtain cardiac CT or usual care, patients will be followed for 5 years (with assessment of outcomes at every 6 months) to see any difference in control of systolic blood pressure. The outcome with be assessed as both a continuous measure, as well as a categorical variable (<135 mm Hg, and >=135 mmHg)

  • Control of LDL cholesterol [ Time Frame: 5 years ]
    We will assess the control of LDL cholesterol at 6 month intervals for a total of 5 years. We will assess this measure as a continuous variable and as a a dichotomous outcome (LDL < or = 100 or LDL >100)

  • Hemoglobin A1c [ Time Frame: 5 years ]
    After the cardiac CT, we will assess if patients have better control of their hemoglobin A1c (we will assess every 6 months for a total of 5 years). This will be a continuous measure.

Enrollment: 198
Study Start Date: July 2008
Study Completion Date: December 2016
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cardiac CT
Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
Procedure: Cardiac CT
A cardiac CT involves a non-invasive test of the coronary arteries.
Placebo Comparator: Usual Care
Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
Drug: Usual medical care
Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
Other Name: Usual medical care would include control of blood pressure, blood glucose, and cholesterol by the primary care physician.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age > 18
  • Diabetes
  • Metabolic Syndrome

Exclusion Criteria:

  • Symptoms of heart disease
  • Heart Disease
  • Renal disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01564485

United States, California
University of California, Irvine Medical Center
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine
Principal Investigator: Shaista Malik, MD, PhD University of California, Irvine
  More Information

Responsible Party: Shaista Malik, Assistant Professor, University of California, Irvine Identifier: NCT01564485     History of Changes
Other Study ID Numbers: 20086170
Study First Received: February 24, 2012
Last Updated: December 7, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Diabetes Mellitus
Metabolic Syndrome X
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Insulin Resistance
Hyperinsulinism processed this record on September 21, 2017